ACM
PSTV

AIGH Capital Management’s Plus Therapeutics PSTV Stock Holding History

AIGH Capital Management’s Portfolio PSTV Stock Details PSTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-22,436
Closed -$645K – 47
2024
Q4 		$645K Hold
22,436
– – 0.2% 34
2024
Q3 		$819K Sell
22,436
-311
-1% -$12.3K 0.23% 34
2024
Q2 		$836K Buy
+22,747
New +$1.12M 0.26% 32

Other funds holding PSTV

HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $50.7M AUM 30.19% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIGH Capital Management's PSTV Position: Q1 2025 in Review

AIGH Capital Management sold out of Plus Therapeutics (PSTV) in Q1 2025, closing a stake of 22,436 shares — an estimated $645K sold.

AIGH Capital Management first reported a position in PSTV in Q2 2024 and held it in 3 quarters. The position peaked at $836K in Q2 2024. 15 funds tracked by Wall St. Rank hold PSTV as of Q1 2025.

  • AIGH Capital Management reported no remaining Plus Therapeutics position as of Q1 2025 after selling out during the quarter.
  • AIGH Capital Management sold 22,436 Plus Therapeutics shares in Q1 2025, an estimated $645K.
  • AIGH Capital Management first reported a position in Plus Therapeutics in Q2 2024 and held it in 3 quarters.
  • AIGH Capital Management's Plus Therapeutics position peaked at $836K in Q2 2024.
  • 15 funds tracked by Wall St. Rank held Plus Therapeutics as of Q1 2025.

Based on AIGH Capital Management's 13F filing for Q1 2025, filed 6 May 2025.